Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Rajni Sinha
A Phase II Study of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Indolent Non-Hodgkin's Lymphoma
British Journal of Haematology
Hematology
Initial Management Strategies for Follicular Lymphoma
International Journal of Hematologic Oncology
Oncology
Hematology
Pharmacology
Related publications
Pegylated Liposomal Doxorubicin Combined With Cyclophosphamide, Vincristine/Vindesine, and Prednisone in Patients With Aggressive T-Cell Lymphoma: Preliminary Results of Aphase Ii Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Accept: A Phase Ib/Ii Combination of Acalabrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-Chop) for Patients With Diffuse Large B-Cell Lymphoma (Dlbcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma
Leukemia and Lymphoma
Cancer Research
Oncology
Hematology
A Phase II Study of Ibrutinib in Combination With Rituximab-Cyclophosphamide-Doxorubicin Hydrochloride-Vincristine Sulfate-Prednisone Therapy in Epstein-Barr Virus-Positive, Diffuse Large B Cell Lymphoma (54179060LYM2003: IVORY Study): Results of the Final Analysis
Annals of Hematology
Medicine
Hematology
Characteristics and Management of Rash Following Lenalidomide and Rituximab in Patients With Untreated Indolent Non-Hodgkin Lymphoma
Haematologica
Hematology
A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
British Journal of Haematology
Hematology
Role of Radiotherapy in Diffuse Large B‐cell Lymphoma in Advanced Stages on Complete Response After Administration of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab
Precision Radiation Oncology
Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 With and Following Rituximab in Patients With Recurrent Indolent and Aggressive Non Hodgkin's Lymphoma
Clinical Cancer Research
Cancer Research
Oncology
